Newsfeeds - Spark Newswire

1 minute read

CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program

Today, 2:00 PM

CymaBay Therapeutics Inc (NASDAQ:CBAY) has received $100 million in non-dilutive financing from Abingworth to fund the Phase 3 development program for seladelpar in…

CBAY

2 minute read

CymaBay Announces $100M Non-Dilutive Financing With Abingworth

By Bill Haddad

Today, 2:00 PM

Risk-sharing agreement with Abingworth will fund seladelpar Phase 3 development program for PBC CymaBay retains full worldwide commercial rights to seladelpar NEWARK, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) --

CBAY

8 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For June 14, 2021

By Benzinga Insights

Today, 2:00 PM

ATLC

1 minute read

Uncategorized

CymaBay Therapeutics Q1 EPS $(0.25) Misses $(0.24) Estimate

By Benzinga Newsdesk

Today, 2:00 PM

CymaBay Therapeutics (NASDAQ:CBAY) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.24) by 4.17 percent. This is a 31.58 percent decrease over losses of $(0.19) per share

CBAY

14 minute read

Uncategorized

Earnings Scheduled For May 13, 2021

By Benzinga Insights

Today, 2:00 PM

Companies Reporting Before The Bell • CASI Pharmaceuticals (NASDAQ:CASI) is estimated to report quarterly loss at $0.06 per share on revenue of $5.05 million.

AACG

Latest news

CymaBay Secures $100M Non-Dilutive Funding To Fund Seladelpar Development Program

CymaBay Announces $100M Non-Dilutive Financing With Abingworth

Benzinga’s Top Ratings Upgrades, Downgrades For June 14, 2021

CymaBay Therapeutics Q1 EPS $(0.25) Misses $(0.24) Estimate

Earnings Scheduled For May 13, 2021